MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » FDA clears Verily Study Watch for additional capabilities

FDA clears Verily Study Watch for additional capabilities

By

Verily Study Watch
Verily’s Study Watch [Image courtesy of Verily]
Verily, Google’s life science’s sister company under Alphabet (NSDQ:GOOGL), has received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable.

The FDA announcement, last updated Jan. 20, did not include additional information. The agency cleared ECG capabilities on the Study Watch in January 2019.

Launched in April 2017, the Study Watch has found use among thousands of people participating in clinical trials, according to Verily. The company touts the Study Watch’s unobtrusive biosensing, which includes built-in biometric, environmental and movement sensors.

Pharmaceutical industry giants including Novartis, Otsuka, Pfizer and Sanofi formed a strategic alliance with Verily last year to develop patient-centered clinical research programs using Verily’s Project Baseline evidence generation platform and tools, including the Study Watch.

More recent news

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.